Researchers have developed a new method to treat multiple myeloma, a type of blood cancer. They engineered a type of immune cell called T cells to produce and release special proteins. These proteins act like bridges, connecting the engineered T cells to cancer cells that have a specific marker called B7-H3, thereby activating the T cells to kill the cancer. In lab tests, these “ENG-T cells” effectively killed multiple myeloma cells, especially those with higher levels of the B7-H3 marker. This new approach aims to overcome challenges faced by existing immune therapies for multiple myeloma, such as cancer cells becoming resistant. The results suggest this could be a promising future treatment that may improve outcomes for patients.
Funding
–
Original Paper
Title of original paper: Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach.
Journal: Journal of Translational Medicine (J Transl Med)
DOI: 10.1186/s12967-024-05923-z
Correspondence
Mutita Junking, E-mail: [email protected]
Pa-Thai Yenchitsomanus, E-mail: [email protected]
Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.